

The deal will significantly increase the scale of DCC's pharma business, bringing in a complementary product portfolio, product licences and strong relationships with UK retail pharmacies. Combined, the two companies will have revenues approaching €150m and a leading position in the UK generics market.
Kent Pharma has a broad portfolio of licensed products with a particular focus on beta lactam antibiotics including penicillin V, flucloxacillin and amoxicillin for treating bacterial infections. The Company also operates Athlone Pharmaceuticals, a specialist beta lactam manufacturing facility located in Roscommon, Ireland.
Commenting on the transaction Mike Overy, Kent Pharmaceutical's Chairman, said:
"Gordon did a fantastic job advising on a very complex sale involving multiple stakeholders. Gordon's deep sector knowledge and proven execution capabilities were integral to the successful completion of this transaction".